FREQ Company Profile and Key Details
Frequency Therapeutics, Inc.
FREQ Stock Price Chart
Stock Price Today
Frequency Therapeutics, Inc. (FREQ) stock surged +4.76%, trading at $0.30 on NASDAQ, up from the previous close of $0.29. The stock opened at $0.29, fluctuating between $0.28 and $0.32 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Company Information
| Employees | 46 |
| Beta | 0.77 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Frequency Therapeutics, Inc. (NASDAQ: FREQ) stock price is $0.30 in the last trading session. During the trading session, FREQ stock reached the peak price of $0.32 while $0.28 was the lowest point it dropped to. The percentage change in FREQ stock occurred in the recent session was 4.76% while the dollar amount for the price change in FREQ stock was $0.01.
The NASDAQ listed FREQ is part of Biotechnology industry that operates in the broader Healthcare sector. Frequency Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Wendy S. Arnold
Chief People Officer
Mr. Jason Glashow
Senior Vice President of Corporation Affairs
Dr. William W. Chin M.D.
Senior Vice President of Translational Medicine
Mr. James P. Abely
Associate Gen. Counsel & Sec.
Dr. Christopher R. Loose Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Richard J. Mitrano
Vice President of Fin. & Operations
Dr. Dana C. Hilt M.D.
Chief Medical Officer (acting)
Mr. David L. Lucchino
Co-Founder, Pres, Chief Executive Officer & Director
Dr. John L. LaMattina Ph.D.
Senior Advisor & Member of PCA Regenerative Medicine Advisory Board
Dr. Carl P. LeBel Ph.D.
Chief Devel. Officer
Dr. Lisa Geller J.D., Ph.D.
Senior Vice President of Intellectual Property
Dr. Quentin McCubbin Ph.D.
Chief Manufacturing Officer
FREQ's closing price is 63.72% higher than its 52-week low of $0.18 where as its distance from 52-week high of $5.59 is -94.64%.
Number of FREQ employees currently stands at 46.
Official Website of FREQ is: https://www.frequencytx.com
FREQ could be contacted at phone 781 315 4600 and can also be accessed through its website. FREQ operates from 75 Hayden Avenue, Lexington, MA 02421, United States.
FREQ stock volume for the day was 309.16K shares. The average number of FREQ shares traded daily for last 3 months was 135.08K.
The market value of FREQ currently stands at $10.94M with its latest stock price at $0.30 and 36.52M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com